<DOC>
	<DOCNO>NCT01426100</DOCNO>
	<brief_summary>The aim present study evaluate efficacy safety two dose combination Telmisartan/S-Amlodipine ( 40/2.5mg 40/5mg ) compare telmisartan monotherapy ( 80mg ) hypertensive patient inadequately control telmisartan monotherapy .</brief_summary>
	<brief_title>CKD-828 Telmisartan Non-Responder Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>age 18 year old diagnosis essential hypertension blood pressure adequately control ( inadequate control define seat diastolic blood pressure ( DBP ) &gt; = 90mmHg exist antihypertensive treatment seat DBP &gt; = 100mmHg treatment naive ) failure respond four week treatment telmisartan 40mg ( failure respond define seat DBP &gt; = 90mmHg ) willing able provide write informed consent mean seat DBP &gt; = 120mmHg and/or mean seat SBP &gt; = 200mmHg runin treatment mean seat DBP &gt; = 120mmHg and/or mean seat SBP &gt; = 180mmHg randomization visit know suspected secondary hypertension ( ex . aortic coarctation , Primary hyperaldosteronism , renal artery stenosis , pheochromocytoma ) severe heart disease ( Heart failure NYHA functional class 3 , 4 ) , unstable angina myocardial infarction , arrhythmia within past three month cerebrovascular disease cerebral infarction , cerebral hemorrhage within 6 month Type I Diabetes Mellitus , Type II Diabetes Mellitus poor glucose control define fast glucosylated hemoglobin ( HbA1c ) &gt; 8 % nown severe malignant retinopathy hepatic renal dysfunction define follow laboratory parameter : AST/ALT &gt; UNL X 2 , serum creatinine &gt; UNL X 1.5 acute chronic inflammatory status need treatment need additional antihypertensive drug study need concomitant medication know affect blood pressure study history angioedema related ACE inhibitor Angiotensin II Receptor Blockers know hypersensitivity relate either study drug history drug alcohol dependency within 6 month surgical medical condition might significantly alter absorption , distribution , metabolism , excretion investigational product ( ex . gastrointestinal tract surgery gastrectomy , gastroenterostomy bypass , active inflammatory bowel syndrome within 12 month prior screen , gastric ulcer need treatment , gastrointestinal/rectal bleeding , impaired pancreatic function pancreatitis , obstruction urinary tract difficulty void administration study drug within 30 day prior randomization premenopausal woman ( last menstruation &lt; 1year ) use adequate contraception , pregnant breastfeed history malignancy include leukemia lymphoma within past 5 year investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>CKD-828</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Primary Hypertension</keyword>
	<keyword>S-Amlodipine</keyword>
	<keyword>Telmisartan</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Non-Responder</keyword>
</DOC>